WARNER BRENT (President, Gene Therapy) received a stock award from POSEIDA THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 3/2/2023ACC: 0001209191-23-014910
Officer· President, Gene Therapy
Since Feb 2022
+191.44K
Net shares
Net buyer
$142.4K
Total sold
0
Open market trades
0B · 0S
3
Total transactions
218.06K acquired · 26.62K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+92.77K
Price / share
—
Trade value
—
% of position
30.1%
3/1/2023
307.88K→400.65K
Common Stock
Direct
Shares
−26.62K
Price / share
$5.35
Trade value
$142.40K
% of position
6.6%
3/1/2023
400.65K→374.04K
Total
Net shares
+66.16K
Net value
-$142.40K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/1/2023 | A · Award | +92.77K | — | — | 30.1% | 307.88K | 400.65K |
| Common Stock Direct | 3/1/2023 | F · Tax Withholding | −26.62K | $5.35 | $142.40K | 6.6% | 400.65K | 374.04K |
| Total | +66.16K | -$142.40K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
125.28K shares
Shares
+125.28K
Strike price
5.35
Held after
125.28K
Exercisable
—
3/1/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock125.28K shares | 3/1/2023 | A · Award | +125.28K | 5.35 | — | 125.28K |